These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease. Kerstens VS, Fazio P, Sundgren M, Matheson GJ, Franzén E, Halldin C, Cervenka S, Svenningsson P, Varrone A. EJNMMI Res; 2020 Aug 14; 10(1):95. PubMed ID: 32797307 [Abstract] [Full Text] [Related]
7. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients. Sonni I, Fazio P, Schain M, Halldin C, Svenningsson P, Farde L, Varrone A. J Nucl Med; 2016 Oct 14; 57(10):1529-1534. PubMed ID: 27230923 [Abstract] [Full Text] [Related]
8. [18F]FE-PE2I DAT correlates with Parkinson's disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study. Kerstens VS, Fazio P, Sundgren M, Halldin C, Svenningsson P, Varrone A. EJNMMI Res; 2023 Apr 05; 13(1):29. PubMed ID: 37017878 [Abstract] [Full Text] [Related]
11. VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT. Jakobson Mo S, Axelsson J, Stiernman LJ, Larsson A, Af Bjerkén S, Bäckström D, Kellgren TG, Varrone A, Riklund K. Nucl Med Commun; 2022 Mar 01; 43(3):247-255. PubMed ID: 34908018 [Abstract] [Full Text] [Related]
13. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs. Bang JI, Jung IS, Song YS, Park HS, Moon BS, Lee BC, Kim SE. Nucl Med Biol; 2016 Feb 01; 43(2):158-64. PubMed ID: 26872440 [Abstract] [Full Text] [Related]
14. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafani M, Bezard E, Esquerré JP, Baulieu JL. J Nucl Med; 2003 May 01; 44(5):663-70. PubMed ID: 12732666 [Abstract] [Full Text] [Related]
15. Simplified quantification of [18F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium. Brumberg J, Kerstens V, Cselényi Z, Svenningsson P, Sundgren M, Fazio P, Varrone A. J Cereb Blood Flow Metab; 2021 Jun 01; 41(6):1291-1300. PubMed ID: 32955955 [Abstract] [Full Text] [Related]
17. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P. Mov Disord; 2018 Jan 01; 33(1):117-127. PubMed ID: 29082547 [Abstract] [Full Text] [Related]
20. Test-retest reproducibility of dopamine transporter density measured with [18F]FP-CIT PET in patients with essential tremor and Parkinson's disease. Son HJ, Oh JS, Oh M, Lee SJ, Oh SJ, Chung SJ, Kim JS. Ann Nucl Med; 2021 Mar 01; 35(3):299-306. PubMed ID: 33387281 [Abstract] [Full Text] [Related] Page: [Next] [New Search]